Background: Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia
| INTRODUCTION
contribute to the development of autoimmune diseases, such as type 1 diabetes mellitus, 5 multiple sclerosis, 6 systemic lupus erythematous 7 and acquired aplastic anaemia. 8 It remains unknown, however, when and how Tregs become impaired before or during very early disease development.
In this regard, drug-induced hypersensitivity syndrome (DiHS)/ drug reaction with eosinophilia and systemic symptoms (DRESS), a distinct phenotype of severe drug eruptions, offers a unique opportunity to link impaired Treg function to subsequent development of autoimmune disease: this is because DiHS/DRESS is characterized by expansions of fully functional Tregs associated with sequential reactivations of latent herpesviruses at the acute stage, followed by subsequent development of autoimmune manifestations occurring long after clinical resolution, possibly reflecting a progressive loss of Treg function. 4, [9] [10] [11] [12] Such a long time interval, however, makes it difficult to link a loss of Treg function and autoimmune manifestations. 13 Indeed, we are, at present, unable to determine which immunological alterations are prerequisite for a progressive loss of Treg function after resolution of DiHS/DRESS. Th17 and Treg cell differentiation is plastic, 14 and Tregs have the propensity to differentiate into Th17 cells in the absence of TGF-β 1, 14,15 after exposure to IL-6. 16 In addition, recent studies have also indicated that the expansion of Th17 cells is favoured by the progressive loss of Tregs leading to chronic graft-vs-host disease (cGVHD), 17 in which reactivations of herpesviruses can be typically observed in the same sequential order as observed in DiHS/DRESS. 18 Thus, we can postulate that resolution of DiHS/DRESS may be accompanied by a shift away from Treg differentiation towards Th17 cell differentiation.
We therefore performed a prospective longitudinal study on the frequencies of Tregs and Th17 cells after onset of the disease and long after clinical resolution. Prompted by recent reports on a close interaction between Tregs and monocyte subsets, 19 we also sought to characterize monocyte populations during the course of DiHS/ DRESS, and determine whether monocyte subsets could have strong impact on the Th17 and Treg cell differentiation. 
| Identification of monocyte subpopulations
PBMCs were gated on the putative monocyte fraction, including a portion of the adjacent lymphocytes, as demonstrated previously. 
| Immunohistochemical detection of pMOs in skin lesions
Immunohistochemical detection of CD16 and paired immunoglobulin-like type 2 receptor α (PILR-α) on pMOs in skin lesions was performed using skin biopsy specimens from DiHS/DRESS and SJS/TEN skin lesions, as previously described. 4 Immunoreactivity was detected using AEC Liquid Substrate Chromogen (K3463, Dako). For detection of CD16 and PILR-α, mAb to CD16 purchased from Novocastra 
| Statistical analysis
Data are expressed as mean ± SEM. Significance of differences between the groups was determined using Student's t test, Welch's t test and Fisher's exact probability test. To assess correlations, Spearman's correlation coefficient was used. Significance was defined as P value of 0.05 or less for all tests. Table S1 .
A recent study 24 Figure S2 ). [19] [20] [21] [22] [23] Among them, pMOs have been reported to patrol the whole body for signs of infection 26, 27 and control peripheral Treg development in immune thrombocytopenia. 19 We therefore investigated whether MOs, particularly pMOs, would − iTregs ( Figure 6 and Figure S5 ). Tregs in patients with DiHS/ DRESS at the acute stage (n = 31) and at the resolution stage (n = 21) and SJS/TEN at the acute stage (n = 18) and the resolution stage (n = 15) and healthy controls (n = 17). Results are expressed as the mean ± SEM. Fr., Fraction *,P < 0.05, **,P < 0.01 USHIGOME ET AL.
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The ability of cMOs to expand iTregs was significantly higher than that of pMOs when cMOs from healthy controls were used Although a more complex scenario than that provided by our study could exist in a number of diverse physiological and pathological settings, this complex interaction should be a therapeutic target and the outcome of the disease may depend on how we can control the interaction.
A previous study proposed an inflammatory role for pMOs in the pathogenesis of SJS/TEN. 31 Indeed, we demonstrate that PILR-α and HVEM, which can specifically bind to HSV gB and gD, respectively, are preferentially In conclusion, we found that MOs from the acute stage of DiHS/ DRESS are more prone to expand iTregs due to the relative increase in cMOs with the potent ability to expand iTregs to cMOs, whereas those at the resolution stage are likely to induce Th17 cell development due to reappearance of pMOs preferentially producing IL-6
( Figure S6 ) that may be different from the original population. Our study supports the concept that the major therapeutic target for severe drug eruptions is the MO subsets that can drive the shift from a Treg to a Th17 development.
